AU707144B2 - Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect - Google Patents

Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect Download PDF

Info

Publication number
AU707144B2
AU707144B2 AU25052/97A AU2505297A AU707144B2 AU 707144 B2 AU707144 B2 AU 707144B2 AU 25052/97 A AU25052/97 A AU 25052/97A AU 2505297 A AU2505297 A AU 2505297A AU 707144 B2 AU707144 B2 AU 707144B2
Authority
AU
Australia
Prior art keywords
denotes
thalidomide
acid
amino
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU25052/97A
Other languages
English (en)
Other versions
AU2505297A (en
Inventor
Michaela Akermann
Kurt Eger
Johannes Schneider
Werner Winter
Stephan Wnendt
Kai Zwingenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Chemie Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH, Chemie Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of AU2505297A publication Critical patent/AU2505297A/en
Application granted granted Critical
Publication of AU707144B2 publication Critical patent/AU707144B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
AU25052/97A 1996-04-09 1997-03-22 Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect Ceased AU707144B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19613976A DE19613976C1 (de) 1996-04-09 1996-04-09 Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
DE19613976 1996-04-09
PCT/EP1997/001475 WO1997037988A1 (de) 1996-04-09 1997-03-22 Acylierte n-hydroxymethyl thalidomid-prodrugs mit immunomodulatorischer wirkung

Publications (2)

Publication Number Publication Date
AU2505297A AU2505297A (en) 1997-10-29
AU707144B2 true AU707144B2 (en) 1999-07-01

Family

ID=7790778

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25052/97A Ceased AU707144B2 (en) 1996-04-09 1997-03-22 Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect

Country Status (12)

Country Link
US (1) US6417197B1 (enExample)
EP (1) EP0892794B1 (enExample)
JP (1) JP2000508298A (enExample)
CN (1) CN1102931C (enExample)
AT (1) ATE212989T1 (enExample)
AU (1) AU707144B2 (enExample)
DE (2) DE19613976C1 (enExample)
DK (1) DK0892794T3 (enExample)
ES (1) ES2171923T3 (enExample)
HU (1) HUP9902181A3 (enExample)
PT (1) PT892794E (enExample)
WO (1) WO1997037988A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
WO1997045117A1 (en) * 1996-05-29 1997-12-04 Prototek, Inc. Prodrugs of thalidomide and methods for using same as modulators of t-cell function
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE19743968C2 (de) * 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
CZ299808B6 (cs) * 1997-11-18 2008-12-03 Celgene Corporation Substituované 2-(2,6-dioxo-3-fluoropiperidin-3-yl)izoindoliny a jejich použití za úcelem snížení hladin TNFalfa
WO2001041755A2 (en) * 1999-12-02 2001-06-14 The Regents Of The University Of Michigan Topical compositions comprising thalidomide for the treatment of inflammatory diseases
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
CN100488959C (zh) * 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
WO2005016326A2 (en) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CN100398534C (zh) * 2003-09-15 2008-07-02 天津和美生物技术有限公司 合成酞胺哌啶酮及其衍生物的方法
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US7973057B2 (en) 2003-09-17 2011-07-05 The United States Of America As Represented By The Department Of Health And Human Services Thalidomide analogs
KR20060118472A (ko) * 2003-10-16 2006-11-23 카이론 코포레이션 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
WO2007120669A1 (en) 2006-04-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
PT2358697E (pt) 2008-10-29 2016-02-03 Celgene Corp Compostos de isoindolina para utilização no tratamento do cancro
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
SG11201805779TA (en) * 2016-01-08 2018-08-30 Celgene Corp Antiproliferative compounds, and their pharmaceutical compositions and uses
WO2019036839A1 (zh) * 2017-08-21 2019-02-28 诺瑞特国际药业股份有限公司 泊马度胺衍生物及其制备方法
CN111499610A (zh) * 2019-01-31 2020-08-07 南京诺瑞特医药科技有限公司 泊马度胺前体药物盐的多晶型物
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
CA2104776C (en) * 1991-04-17 2003-12-09 Kurt Eger Thalidomide derivatives, method of manufacture and use thereof in medicaments
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Also Published As

Publication number Publication date
US6417197B1 (en) 2002-07-09
PT892794E (pt) 2002-07-31
HUP9902181A3 (en) 2002-11-28
AU2505297A (en) 1997-10-29
ATE212989T1 (de) 2002-02-15
DK0892794T3 (da) 2002-04-15
EP0892794B1 (de) 2002-02-06
JP2000508298A (ja) 2000-07-04
HUP9902181A2 (hu) 2000-04-28
EP0892794A1 (de) 1999-01-27
WO1997037988A1 (de) 1997-10-16
CN1102931C (zh) 2003-03-12
HK1017350A1 (en) 1999-11-19
CN1215397A (zh) 1999-04-28
DE59706313D1 (de) 2002-03-21
DE19613976C1 (de) 1997-11-20
ES2171923T3 (es) 2002-09-16

Similar Documents

Publication Publication Date Title
AU707144B2 (en) Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect
CS228119B2 (en) Production of n2-arylsulphonyl-l-argininamides
JPH08508720A (ja) ピロールーアミジン化合物およびその薬剤的に受容できる塩、その製造法ならびにこれを含む医薬組成物
DK155792B (da) Analogifremgangsmaade til fremstilling af pyrrol-eddikesyreamider eller salte deraf
JP2026016715A (ja) 狂犬病治療のための環状アミド化合物およびその方法
US4839387A (en) Derivative of thiazolidine-4-carboxylic acid, its preparation and pharmaceutical compositions containing it
FI92707B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten estramustiiniestereiden valmistamiseksi
CA2251060C (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
US4228183A (en) Novel phenethylamine derivatives and processes for preparing same
JPH02124884A (ja) Ｎ―置換アミド誘導体
RU2029771C1 (ru) Оптически активные производные пиридобензоксазина или их соли
CN1212317C (zh) 新颖的酯或酰胺衍生物
MXPA98007998A (en) Acrylic prodrogas of n-hydroxymethyl talidomide with immunomodula activity
JPS63502432A (ja) アシル化シアナミド組成物
HK1017350B (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
HK1019588A (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
JP2802778B2 (ja) ホモピペラジン誘導体及びこれを含有する脳保護剤
JP2023084946A (ja) 生理活性を有する新規化合物
JPH11512735A (ja) プリンとグアニンの誘導体
JPS584770A (ja) 抗高血圧剤としてのイソキノリンカルボン酸誘導体
CN1970559A (zh) β－咔啉生物碱及其制备方法与应用
JPH0688974B2 (ja) ２−ピリジルアセタミド誘導体、その製法および用途
JPH11322593A (ja) アセトアミド誘導体を有効成分とする抗癌剤及びチュ―ブリン阻害剤、並びに新規アセトアミド誘導体
JPH0432077B2 (enExample)
JPS63284170A (ja) 新規グアニジノメチル−チオフエンカルボン酸誘導体